Please login to the form below

Not currently logged in
Email:
Password:

Alliance Pharma names non-executive director

Nigel Clifford to assume the role with immediate effect
Nigel Clifford

Alliance Pharma has appointed Nigel Clifford as an independent non-executive director, with immediate effect.

Clifford is chief executive at Procserve Holdings, which enables secure transactions online, and is additionally a non-executive director of software solutions firm Anite.

Commenting on the appointment, Andrew Smith, chairman of Alliance, said: “We are delighted to welcome Nigel to the board of Alliance. His breadth of business experience and his significant exposure to international and European markets make him a strong addition to the Alliance team.”

Clifford has previously held multiple relevant roles such as CEO at Micro Focus International, Symbian Software and Tertio Telecoms, as well as other senior positions at Nokia, Glasgow Royal Infirmary NHS Trust and BT.

Alliance is a pharma firm based in Chippenham, UK, with the ownership or licensing rights to over 60 products.

5th February 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics